Bone News and Research

RSS

Scientists develop new mathematical model to understand CML better

Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States. The work, to be published in the June edition of the journal Haematologica, also reveals that current therapies - which are not believed to cure CML - with the right protocol can actually get rid of the disease, and provides guidelines on how to do that.

21 Feb 2010

OrthoAccel Technologies promotes AcceleDent System for enhancing orthodontics at 7th IOC

OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device to enhance orthodontics, recently exhibited at the 7th International Orthodontic Congress (IOC) in Sydney, Australia, which is held by the World Federation of Orthodontists (WFO) every five years. The 8th IOC in 2015 will be hosted in London.

20 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Genoptix, Inc., a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it.

19 Feb 2010

Most important osteoporosis meeting of 2010: More than 850 abstracts received

More than 850 abstracts have been received - guaranteeing broad global attendance at the year's most noteworthy platform for osteoporosis research. Don't miss the most important osteoporosis meeting of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

19 Feb 2010

U.S. Patent and Trademark office issues Patent on Positron’s Tech-Assist

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, announced today that the U.S. Patent and Trademark office has allowed for issuance a Patent on Positron’s Tech-Assist™. The Tech-Assist™, invented under the direction of John A. Zehner, a nuclear pharmacist, dramatically reduces exposure to the worker while injecting radiopharmaceuticals into patients when performing Positron Emission Tomography (PET) imaging studies.

19 Feb 2010

Six states to study sickle cell disease and thalassemias in national pilot project

Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.

19 Feb 2010

Researchers find gene mutations that may provide clues for treating AML patients

Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin.

19 Feb 2010

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

Since the brain-injuring virus needs mosquitoes and pigs to spread, government officials should ban standing water in cemetery cisterns and urban drainage ditches. They should keep industrial "piggeries" away from cities and their populations.

19 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Fourth-quarter and fiscal year 2009 results announced by DJO Incorporated

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC (“DJOFL”), for the fourth quarter and fiscal year ended December 31, 2009. ReAble Therapeutics, Inc. (“ReAble”) acquired DJO Incorporated (“DJO Opco”) in a transaction completed on November 20, 2007 (the “DJO Merger”).

18 Feb 2010

Vertebroplasty effective in treatment of VCFs

The results of a study of more than 4500 patients from six Italian EVEREST (European Vertebroplasty Research Team) Centers (Dr. G.C. Anselmetti-Candiolo Torino, Dr. G. Bonaldi-Bergamo, Dr. P. Carpeggiani-Pisa, Dr. S. Masala-Roma, Dr. M. Muto-Napoli,) confirms the effectiveness of vertebroplasty in treating vertebral compression fractures (VCFs), finding that the procedure provides significant and sustained pain relief.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Eriez unveils new Dual-Beam X-Ray and Metal Detector systems for improved food safety

Eriez®, world authority in magnetic, vibratory and inspection applications, has introduced an extra wide combination E-Z Tec® Dual-Beam Multi-Zone X-Ray and Metal Detector System.

18 Feb 2010

BioMimetic Therapeutics annouces completion of Augment Bone Graft PMA submission

BioMimetic Therapeutics, Inc. today announced it has submitted the third and final module of its Premarket Approval (PMA) application for marketing of Augment™ Bone Graft in the U.S. This final module, containing a comprehensive review of the clinical data related to Augment, completes the PMA application to the FDA. The Company previously announced the filing of both the pre-clinical pharmacology/toxicology and quality/manufacturing modules with the FDA in June of 2009.

18 Feb 2010

BrainStorm Cell Therapeutics secures funds for ALS clinical trials

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has entered into agreements with three investors with each investing $500,000 for a total of investment of $1.5 million into BrainStorm.

18 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

SBi introduces 10-minute new surgical technique DVD for hand surgeons

Small Bone Innovations, Inc., a leading, privately-held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, is making available to hand surgeons a new 10-minute new surgical technique DVD showing an innovative volar approach to insertion of its SR™ PIP (Proximal Interphalangeal) implant.

17 Feb 2010

Bone News and Research

Scientists develop new mathematical model to understand CML better

OrthoAccel Technologies promotes AcceleDent System for enhancing orthodontics at 7th IOC

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Most important osteoporosis meeting of 2010: More than 850 abstracts received

U.S. Patent and Trademark office issues Patent on Positron’s Tech-Assist

Six states to study sickle cell disease and thalassemias in national pilot project

Researchers find gene mutations that may provide clues for treating AML patients

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

FDA approves Rituxan-FC combination therapy for CLL

Rituxan, intended for patients with CLL receives FDA approval

Fourth-quarter and fiscal year 2009 results announced by DJO Incorporated

Vertebroplasty effective in treatment of VCFs

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Eriez unveils new Dual-Beam X-Ray and Metal Detector systems for improved food safety

BioMimetic Therapeutics annouces completion of Augment Bone Graft PMA submission

BrainStorm Cell Therapeutics secures funds for ALS clinical trials

Genzyme announces fourth-quarter and full-year 2009 financial results

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

SBi introduces 10-minute new surgical technique DVD for hand surgeons

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News